Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Chief Tech Ops Officer | August 05, 2025 | August 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date August 05, 2025 · Filed August 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,250 |
Reported balance
After 2025-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-05 · Grant · Acquired 6,250 · Balance 6,250 F1: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 11, 2026
Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2035-10-07 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option vests over a 4-year period: 25% on October 8, 2026, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Disposition to issuer · Disposed 49,000 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F5: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").
F2: The option vests over a 4-year period: 25% on October 8, 2026, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.
F4: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F5: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date.
F6: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 20:31 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerRestricted Stock Unit · Derivative | 49,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001959750-26-000003 · form4-06112026_080626.xml · derivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F5 · derivative.exercise_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. F5 · derivative.expiration_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:31 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001959750-26-000003 · form4-06112026_080626.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2035-10-07 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option vests over a 4-year period: 25% on October 8, 2026, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:11 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantRestricted Stock Unit · Derivative | 49,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001959750-26-000001 · form4-01212026_090142.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate. F2 · derivative.expiration_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 22:59 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001959750-25-000006 · form4-10082025_101030.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-10-07 F1 · derivative.exercise_date: The option vests over a 4-year period: 25% vests on October 8, 2026, after which 1/48th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 00:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-104399 · ownership.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 16,644 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037524 · ownership.xml · derivative · entry 3 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 Underlying: Common Stock · 16,644 shares Expires 2035-03-10 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037524 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 523 | $100.13 | $52,367.99 |
DisclosureSEC source: 0000950170-25-037524 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,224 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 8,527 | $103.70 | $884,249.90 |
DisclosureSEC source: 0000950170-25-036691 · ownership.xml · nonDerivative · entry 3 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,747 F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 508 | $103.70 | $52,679.60 |
DisclosureSEC source: 0000950170-25-036691 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,274 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036691 · ownership.xml · derivative · entry 4 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036691 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 233 | $101.34 | $23,612.22 |
DisclosureSEC source: 0000950170-25-035005 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,282 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 281 | $101.34 | $28,476.54 |
DisclosureSEC source: 0000950170-25-035005 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,515 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 719 | $103.77 | $74,610.63 |
DisclosureSEC source: 0000950170-25-032761 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,796 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. F2 · balance_after: Amount of Securities Beneficially Owned includes 152 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Restricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-020191 · ownership.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 3,500 shares Expires not disclosed F1 · derivative.exercise_price: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,898 | $163.23 | $636,270.54 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 8 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,363 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 224 | $167.13 | $37,437.12 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 7 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,261 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.91 to $167.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 700 | $166.10 | $116,270.00 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 6 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,485 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.69 to $166.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 300 | $164.61 | $49,383.00 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 5 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,185 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.38 to $164.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,055 | $163.83 | $172,840.65 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 4 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,485 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.35 to $164.18, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 5,580 | $162.31 | $905,689.80 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 3 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,540 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.25 to $163.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,352 | $164.64 | $387,233.28 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,120 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · derivative · entry 10 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · derivative · entry 9 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-077518 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 472 | $123.14 | $58,122.08 |
DisclosureSEC source: 0000950170-24-029533 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,222 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 506 | $120.49 | $60,967.94 |
DisclosureSEC source: 0000950170-24-029533 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,694 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 237 | $125.32 | $29,700.84 |
DisclosureSEC source: 0000950170-24-027494 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,200 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 285 | $125.32 | $35,716.20 |
DisclosureSEC source: 0000950170-24-027494 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,437 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · derivative · entry 6 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-01 F6 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 114 | $126.19 | $14,385.66 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · nonDerivative · entry 5 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,722 F5 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: Amount of Securities Beneficially Owned includes 201 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 457 | $129.71 | $59,277.47 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · nonDerivative · entry 4 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,836 F4 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,543 | $128.58 | $198,398.94 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · nonDerivative · entry 3 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,293 F4 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,836 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 251 | $126.19 | $31,673.69 |
DisclosureSEC source: 0000950170-24-026606 · ownership.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,836 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: Amount of Securities Beneficially Owned includes 201 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 3,682 | $80.34 | $295,811.88 |
DisclosureSEC source: 0001209191-23-057558 · doc4.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,886 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 30, 2021. F2 · balance_after: Amount of Securities Beneficially Owned includes 201 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2023. Read SEC document |
| March 30, 2023 Filed Apr 5, 2023 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 307 | $136.66 | $41,954.62 |
DisclosureSEC source: 0001209191-23-023064 · doc4.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,367 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 29, 2019. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 314 | $153.19 | $48,101.66 |
DisclosureSEC source: 0001209191-23-018018 · doc4.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,674 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017403 · doc4.xml · derivative · entry 4 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-03-06 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017403 · doc4.xml · nonDerivative · entry 3 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,988 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 154 | $157.21 | $24,210.34 |
DisclosureSEC source: 0001209191-23-017403 · doc4.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,488 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 186 | $157.21 | $29,241.06 |
DisclosureSEC source: 0001209191-23-017403 · doc4.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,642 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 172 | $147.57 | $25,382.04 |
DisclosureSEC source: 0001209191-23-016058 · doc4.xml · nonDerivative · entry 2 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,828 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: Amount of Securities Beneficially Owned includes 163 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 80 | $147.57 | $11,805.60 |
DisclosureSEC source: 0001209191-23-016058 · doc4.xml · nonDerivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,837 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Read SEC document |
| December 31, 2022 Filed Jan 5, 2023 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $129.58 | $0.00 |
DisclosureSEC source: 0001209191-23-001464 · doc4.xml · derivative · entry 1 Arif Bilal · CIK 0001959750 · Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-12-31 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.